QualityStocksNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) to File IND, CTA with Health Authorities to Conduct Human Trials of PVT-005 in US and Canada
Pivot Pharmaceuticals (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) this morning announced that it will file an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) and Clinical Trial Application (“CTA”) with Health Canada to begin human clinical trials of its pharmaceutical drug candidate for the treatment of Female Hypoactive Sexual Desire Disorder (“HSDD”), PVT-005. Pivot will employ its drug formulation and delivery platform technologies to develop a topical cream containing cannabinoids for perimenopausal, menopausal and post-menopausal women who have observed a decline in sexual desire and response. "In vitro results from our contract research laboratory indicated…